
CHE
Chemed Corp
- Overview
- Forecast
- Valuation
- Earnings

Line
|

Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
471.320
Open
464.250
VWAP
464.62
Vol
218.39K
Mkt Cap
6.77B
Low
459.5089
Amount
101.47M
EV/EBITDA(TTM)
13.90
Total Shares
15.08M
EV
6.65B
EV/OCF(TTM)
18.17
P/S(TTM)
2.82
Chemed Corporation is engaged in purchasing, operating, and divesting subsidiaries in diverse business activities. The Company's segment includes VITAS and the Roto-Rooter. The VITAS segment provides hospice and palliative care services to its patients through a network of physicians, registered nurses, home health aides, social workers, clergy and volunteers. It provides direct medical services to patients, as well as spiritual and emotional counseling to both patients and their families. The Roto-Rooter segment provides plumbing, drain cleaning, excavation, water restoration and other related services to residential and commercial customers. The Roto-Rooter services are provided through a network of Company-owned branches, independent contractors and franchisees. The Company's water restoration services involve the remediation of water and humidity after a flood and are provided to both commercial and residential customers.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2025Q3
FY2025Q2
660.24M
+3.16%
7.080
+3.66%
632.17M
+4.29%
5.637
-0.06%
629.79M
+5.69%
5.075
-7.22%
Estimates Revision
The market is revising Downward the revenue expectations for Chemed Corporation (CHE) for FY2025, with the revenue forecasts being adjusted by -3.05% over the past three months. During the same period, the stock price has changed by -16.68%.
Revenue Estimates for FY2025
Revise Downward

-3.05%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward

-7.71%
In Past 3 Month
Stock Price
Go Down

-16.68%
In Past 3 Month
3 Analyst Rating

39.66% Upside
Wall Street analysts forecast CHE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CHE is 646.67 USD with a low forecast of 640.00 USD and a high forecast of 650.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
0 Hold
0 Sell
Strong Buy

39.66% Upside
Current: 463.020

Low
640.00
Averages
646.67
High
650.00

39.66% Upside
Current: 463.020

Low
640.00
Averages
646.67
High
650.00
BofA
Buy
downgrade
$708 -> $650
2025-06-30
Reason
BofA
Price Target
$708 -> $650
2025-06-30
downgrade
Buy
Reason
BofA lowered the firm's price target on Chemed to $650 from $708 and keeps a Buy rating on the shares. Chemed on Friday said that the Medicare cap will be a $20M, or 4%, headwind in 2025, which is not a surprise given the Q1 disclosures, but admissions in Florida were weaker in April and May, while Roto-Rooter residential was worse than expected, the analyst tells investors in a research note. While the stock will be pressured on the worse 2025, BofA likes the longer-term fundamentals for both Vitas and Roto.
RBC Capital
Ben Hendrix
Outperform
downgrade
$674 -> $640
2025-06-30
Reason
RBC Capital
Ben Hendrix
Price Target
$674 -> $640
2025-06-30
downgrade
Outperform
Reason
RBC Capital analyst Ben Hendrix lowered the firm's price target on Chemed to $640 from $674 and keeps an Outperform rating on the shares. The firm is disappointed to see Medicare cap limitations weigh on the 2025 outlook, though it is also encouraged by VITAS' new CON, which should help the company maintain strong positioning in an increasingly competitive FL market, the analyst tells investors in a research note. RBC adds that headwinds at Roto-Rooter continue with an unanticipated decline in residential volume, which more than offset improving commercial trends.
RBC Capital
Ben Hendrix
Buy
Maintains
$633 → $667
2025-03-14
Reason
RBC Capital
Ben Hendrix
Price Target
$633 → $667
2025-03-14
Maintains
Buy
Reason
RBC Capital raised the firm's price target on Chemed to $667 from $633 and keeps an Outperform rating on the shares after its Q4 earnings beat last month. Chemed expects VITAS ADC momentum to continue in 2025 with the outlook calling for 8.5%-9.0% growth, and the firm is encouraged that Roto-Rooter appears to be normalizing after several quarters of declining revenue, the analyst tells investors in a research note. RBC adds that the company expects modest commercial demand recovery this year for Roto-Rooter leading to low-single-digit growth.
RBC Capital
Ben Hendrix
Buy
Maintains
$697 → $633
2024-11-05
Reason
RBC Capital
Ben Hendrix
Price Target
$697 → $633
2024-11-05
Maintains
Buy
Reason
RBC Capital lowered the firm's price target on Chemed to $633 from $697 and keeps an Outperform rating on the shares after its Q3 earnings. The company delivered solid results with VITAS strength largely offsetting continued Roto-Rooter headwinds, and the firm was also encouraged to see census momentum continue, bolstered by strong hiring, the analyst tells investors in a research note. RBC adds however that its price target cut reflects a roll in its valuation model to next year's estimates.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Chemed Corp (CHE.N) is 19.24, compared to its 5-year average forward P/E of 24.80. For a more detailed relative valuation and DCF analysis to assess Chemed Corp 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Strongly Undervalued
5Y Average PE
24.80
Current PE
19.24
Overvalued PE
26.84
Undervalued PE
22.77
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Strongly Undervalued
5Y Average EV/EBITDA
16.69
Current EV/EBITDA
13.35
Overvalued EV/EBITDA
17.89
Undervalued EV/EBITDA
15.48
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Strongly Undervalued
5Y Average PS
3.42
Current PS
2.62
Overvalued PS
3.66
Undervalued PS
3.19
Financials
Annual
Quarterly
FY2025Q1
YoY :
+9.79%
646.94M
Total Revenue
FY2025Q1
YoY :
+1.53%
96.59M
Operating Profit
FY2025Q1
YoY :
+10.37%
71.76M
Net Income after Tax
FY2025Q1
YoY :
+14.62%
4.86
EPS - Diluted
FY2025Q1
YoY :
-73.11%
19.46M
Free Cash Flow
FY2025Q1
YoY :
-3.07%
30.98
Gross Profit Margin - %
FY2025Q1
YoY :
-3.95%
12.66
FCF Margin - %
FY2025Q1
YoY :
+0.54%
11.09
Net Margin - %
FY2025Q1
YoY :
-4.05%
26.06
ROIC
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
2.6M
USD
3
3-6
Months
2.6M
USD
3
6-9
Months
2.1M
USD
3
0-12
Months
3.0M
USD
5
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
1
75.3K
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds areSelling! The selling amount has increased 158.47% over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
21.3K
Volume
3
6-9
Months
8.2K
Volume
2
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
1
2.0K
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
16.0K
USD
2
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
2.6M
USD
3
3-6
Months
2.6M
USD
3
6-9
Months
2.1M
USD
3
0-12
Months
3.0M
USD
5
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
1
75.3K
USD
Months
0-12
0
0.0
USD
Months
CHE News & Events
Events Timeline
2025-06-30 (ET)
2025-06-30
12:01:44
Chemed falls -14.0%

2025-06-30
10:00:42
Chemed falls -10.1%

2025-06-30
08:35:00
Oppenheimer says Chemed should be down significantly on Vitas Florida Cap impact

Sign Up For More Events
Sign Up For More Events
News
4.5
06-30BenzingaCrude Oil Moves Lower; Joby Aviation Shares Surge
2.0
06-30CNBCStocks making the biggest moves midday: Hewlett Packard Enterprise, Robinhood, Palantir, Oracle, and more
3.0
06-27Yahoo FinanceChemed To Report Second-Quarter 2025 Earnings July 29, 2025
Sign Up For More News
People Also Watch

SARO
StandardAero, Inc.
28.350
USD
-1.36%

FSV
FirstService Corp
194.000
USD
+8.34%

PAC
Grupo Aeroportuario del Pacifico SAB de CV
222.910
USD
+0.24%

LTM
LATAM Airlines Group SA
41.700
USD
-1.79%

AGI
Alamos Gold Inc
25.720
USD
-1.91%

SKM
SK Telecom Co Ltd
22.420
USD
-0.88%

KT
KT Corp
20.950
USD
-0.57%

FRHC
Freedom Holding Corp
170.550
USD
+0.71%

MTCH
Match Group Inc
34.085
USD
+0.63%

ASR
Grupo Aeroportuario del Sureste SAB de CV
305.040
USD
-0.31%
FAQ

What is Chemed Corp (CHE) stock price today?
The current price of CHE is 463.02 USD — it has decreased -0.66 % in the last trading day.

What is Chemed Corp (CHE)'s business?

What is the price predicton of CHE Stock?

What is Chemed Corp (CHE)'s revenue for the last quarter?

What is Chemed Corp (CHE)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Chemed Corp (CHE)'s fundamentals?

How many employees does Chemed Corp (CHE). have?
